EU/3/12/1009: Orphan designation for the treatment of Duchenne muscular dystrophy



On 4 July 2012, orphan designation (EU/3/12/1009) was granted by the European Commission to Italfarmaco S.p.A., Italy, for givinostat for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
Intended use
Treatment of Duchenne muscular dystrophy
Orphan designation status
EU designation number
Date of designation
Italfarmaco SpA
Via dei Lavoratori, 54
20092 Cinisello Balsamo (MI)
Tel. +39 0264 4325 84
Fax +39 0264 4335 54

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating